PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN
Therapeutic methods are disclosed herein.
1 .- 11 . (canceled)
12 . A method comprising administering an ophthalmically acceptable emulsion comprising cyclosporin A to a mammal that has ceased receiving a therapeutically active agent comprising fluorouracil, wherein the method is effective in treating abnormal lacrimation.
13 . The method of claim 12 , wherein the ophthalmically acceptable emulsion comprises cyclosporin A at a concentration of about 0.05%.
14 . The method of claim 13 , wherein the ophthalmically acceptable emulsion further comprises castor oil, polysorbate 80, and high molecular weight co-polymers of acrylic acid and a long chain alkyl methacrylate cross-linked with allyl ethers of pentaerythritol.
15 . The method of claim 13 , wherein the abnormal lacrimation is associated with keratoconjunctivitis.
16 . The method of claim 13 , wherein the abnormal lacrimation is the result of keratoconjunctivitis.
17 . The method of claim 15 , wherein the keratoconjunctivitis is associated with the therapeutically active agent.
18 . The method of claim 16 , wherein the keratoconjunctivitis is associated with the therapeutically active agent.
19 .- 24 . (canceled)